Pancreatic Cancer

These findings suggest that therapeutic inhibition of FA synthesis may be promising for treating PDAC patients with active c-Myc/GRPEL1/FASN signaling. Overall, this study demonstrates that FA synthesis mediated by the c-Myc/GRPEL1/FASN axis is essential for PDAC growth.

Due to diagnostic ambiguity, surgical resection is often mandated.We present a case of a female patient in her sixth decade of life presenting with symptoms pointing towards a malignant pancreatic head tumour. She underwent formal pancreatoduodenectomy, which on histopathological examination was diagnosed as a schwannoma.

Neoadjuvant SBRT achieves oncologic outcomes comparable to CFRT in BR/LA PC and is associated with greater adjuvant therapy use. A potential survival signal for SBRT in patients receiving FOLFIRINOX with CA19-9 > 1500U/mL is hypothesis-generating and warrants validation and formal interaction testing.

Furthermore, CCR6 inhibition potentiated the efficacy of anti-PD1 immune checkpoint blockade. Taken together, our data demonstrate that tumor cell-derived CCL20 shapes an immunosuppressive microenvironment in pancreatic cancer by recruiting CCR6+ Tregs, suggesting that targeting the CCL20-CCR6 axis offers a promising therapeutic strategy, particularly when combined with immune checkpoint blockade.

P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting

P1, N=220, Recruiting, Poitiers University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Nov 2026 --> Feb 2028

Other immune partners might include vaccines, bispecific antibodies, and cell therapy. A major clinical opportunity eventually would be combining RAS inhibitors and immunotherapy in the adjuvant, neo-adjuvant, and interception settings, provided this new class of drugs is developed keeping its immune modulatory power in mind.

The patient was promptly referred to a specialized hepatobiliary unit for evaluation of curative-intent resection. This case highlights how contemporary high-resolution MRCP combined with extreme CA 19-9 elevation can establish a confident noninvasive diagnosis of Klatskin tumor when initial ERCP fails, dramatically shortening diagnostic delay and accelerating the pathway to potentially curative surgery.

We propose: (1) Refining age-specific GGT thresholds via repeated measurements and restricted cubic splines; (2) Integrating GGT with carbohydrate antigen 19-9, carcinoembryonic antigen, and KRAS/GNAS circulating tumor DNA in machine-learning radiomic models for personalized 5-year malignancy risks per Fukuoka guidelines; and (3) Validating cost-effectiveness in multi-ethnic populations before screening. This repositions GGT as a globally available redox biosignature for PCN early detection, potentially reducing pancreatic cancer burden.